We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+28.11%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$1.82B
AUM Growth
+$1.6B
Cap. Flow
+$16.1M
Cap. Flow %
0.88%
Top 10 Hldgs %
91.96%
Holding
76
New
25
Increased
14
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$8.59M
2
ESPR
Esperion Therapeutics
ESPR
+$7.67M
3
MDT icon
Medtronic
MDT
+$7.27M
4
ICUI icon
ICU Medical
ICUI
+$7.06M
5
EHC icon
Encompass Health
EHC
+$5.8M

Top Sells

Rank Stock Value
1
HOLX
Hologic
HOLX
+$19.2M
2
PFE icon
Pfizer
PFE
+$16.7M
3
SNY icon
Sanofi
SNY
+$15.1M
4
SIBN icon
SI-BONE Inc
SIBN
+$9.12M
5
CI icon
Cigna
CI
+$6.7M

Sector Composition

Rank Sector Weight
1 Healthcare 11.6%
2 Industrials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWN icon
1
PUT
iShares Russell 2000 Value ETF
IWN
$14.3B
$1.55B 85.25%
+108,600
New +$9.88M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$23.9M 1.31%
+77,600
New +$22.7M
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$18.2M 1%
1,396,795
-299,093
-18% -$3.59M
SIBN icon
4
SI-BONE Inc
SIBN
$788M
$11.8M 0.65%
743,380
-578,964
-44% -$9.12M
JNJ icon
5
Johnson & Johnson
JNJ
$618B
$11.8M 0.65%
83,879
+35,388
+73% +$5.16M
CNC icon
6
Centene
CNC
$30.7B
$10.8M 0.59%
170,057
+131,861
+345% +$8.59M
ZTS icon
7
Zoetis
ZTS
$32.4B
$10M 0.55%
73,200
-2,022
-3% -$264K
ESPR
8
DELISTED
Esperion Therapeutics
ESPR
$9.4M 0.52%
+183,249
New +$7.67M
EHC icon
9
Encompass Health
EHC
$11B
$8.74M 0.48%
177,482
+107,575
+154% +$5.8M
ELV icon
10
Elevance Health
ELV
$81.5B
$7.9M 0.43%
30,028
-13,323
-31% -$3.55M
MDT icon
11
Medtronic
MDT
$109B
$6.95M 0.38%
+75,828
New +$7.27M
CI icon
12
Cigna
CI
$73.7B
$6.78M 0.37%
36,122
-35,306
-49% -$6.7M
ICUI icon
13
ICU Medical
ICUI
$4.21B
$6.55M 0.36%
+35,556
New +$7.06M
LH icon
14
Labcorp
LH
$25B
$6.3M 0.35%
44,133
+13,469
+44% +$1.86M
OCUL icon
15
Ocular Therapeutix
OCUL
$1.79B
$6.29M 0.35%
+755,330
New +$5.01M
ABBV icon
16
AbbVie
ABBV
$443B
$6.15M 0.34%
+62,615
New +$5.51M
ZBH icon
17
Zimmer Biomet
ZBH
$18.2B
$5.5M 0.3%
47,419
-49,500
-51% -$5.7M
TRIL
18
DELISTED
Trillium Therapeutics Inc.
TRIL
$5.48M 0.3%
677,823
+200,119
+42% +$1.24M
HMSY
19
DELISTED
HMS Holdings Corp.
HMSY
$5.24M 0.29%
+161,914
New +$4.69M
SNY icon
20
Sanofi
SNY
$103B
$5.1M 0.28%
99,869
-310,092
-76% -$15.1M
RNAC icon
21
Cartesian Therapeutics
RNAC
$229M
$5.05M 0.28%
59,311
+50,801
+597% +$4.6M
ADAP
22
DELISTED
Adaptimmune Therapeutics
ADAP
$4.84M 0.27%
483,103
+323,277
+202% +$2.03M
HOLX
23
DELISTED
Hologic
HOLX
$4.66M 0.26%
81,789
-391,878
-83% -$19.2M
PRTA icon
24
Prothena Corp
PRTA
$425M
$4.22M 0.23%
403,793
+147,844
+58% +$1.64M
HRC
25
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$3.91M 0.21%
35,604
+9,364
+36% +$981K
1
2 3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Endurant Capital Management held 76 positions worth $1.82B, up 727% from $221M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Endurant Capital Management's Q2 2020 filing shows 25 new, 14 increased, 16 reduced and 20 closed positions. Its largest new stake was Esperion Therapeutics: 183,249 shares worth $9.4M. The largest sale was Hologic, an estimated $19.2M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 90% a quarter earlier, followed by Industrials.

  • Endurant Capital Management's largest Q2 2020 buy was Esperion Therapeutics: 183,249 shares worth $9.4M.
  • Endurant Capital Management added most to Centene in Q2 2020, an estimated $8.59M increase.
  • Endurant Capital Management's biggest Q2 2020 reduction was Hologic, cutting an estimated $19.2M.
  • Endurant Capital Management fully exited Pfizer in Q2 2020, selling an estimated $16.7M.
  • Endurant Capital Management's ten largest holdings make up 92% of its $1.82B portfolio in Q2 2020.
  • Endurant Capital Management opened 25 new positions and closed 20 in Q2 2020.
  • Endurant Capital Management's portfolio value rose 727% quarter-over-quarter to $1.82B.

Based on Endurant Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.